Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"With A Molecule That Is A Million Times Larger Than A Small Molecule, So Many Things Can Go Wrong," Says Biogen Idec Asia Operations Head Gunther Winkler

This article was originally published in PharmAsia News

Executive Summary

Gunther Winkler, Biogen Idec's Senior Vice President, International Business, is responsible for expanding the company's Asia operations. Winkler, a close watcher of biosimilars regulations being adapted by various countries, is skeptical about the safety of copied biotech drugs and therefore calls for sufficient caution on the approval mechanism for such drugs. In an interview with PharmAsia News' India bureau, Gunther Winkler spells out the company's ambitions in Asia, which includes research on products that could be relevant to local populations.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts